Clareo Health | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Having radiologically proven brain metastases of lung cancer
Having received whole brain radiotherapy with either 30 grays in 2 weeks or 20 grays in one week. Treatment with enzastaurin must start within 14 days after the last fraction of the whole brain radiotherapy
No other previous radiotherapy to the brain except for radiosurgery at one occasion
Adequate organ function as measured by appropriate laboratory tests.
Age 18 years or older.
You may not be if
Inability to swallow tablets or show conditions which could interfere with oral medication intake (e.g. vomiting, partial bowel obstruction).
Inability to discontinue use of certain anti-epileptic drugs such as, carbamazepine, phenobarbital or phenytoin.
Concurrent administration of warfarin
Hemophilia
Having had any systemic anti-cancer treatment within the last 2 weeks prior to enrolment.
